FDA Approves Vivitrol (naltrexone) for the Treatment for Alcohol Dependence
Vivitrol is a microsphere formulation of the opioid antagonist naltrexone administered once-monthly for the treatment of alcohol dependence.
Posted: April 2006
Related articles
- FDA Approves Vivitrol to Treat Opioid-dependent Patients - October 13, 2010
- Alkermes Announces Submission of Complete Response to FDA for Vivitrol New Drug Application - February 17, 2006
- FDA Issues Approvable Letter for Vivitrol (formerly Vivitrex), for the Treatment of Alcohol Dependence - December 28, 2005
- FDA Extends PDUFA Date for Vivitrex to December 30, 2005 - September 20, 2005
- Alkermes Announces Priority Review Granted For Vivitrex (Naltrexone Long-Acting Injection) NDA Submission - May 27, 2005
- Alkermes Announces Submission of New Drug Application for Vivitrex for Treatment of Alcohol Dependence - April 1, 2005
Vivitrol (naltrexone) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
